Department of Family Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea.
Department of Family Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea.
Eur J Cancer. 2019 Aug;117:5-13. doi: 10.1016/j.ejca.2019.04.033. Epub 2019 Jun 21.
The association between Parkinson's disease (PD) and cancer development is controversial, especially in Asia. Therefore, we conducted a nationwide population-based cohort study to assess the overall cancer risk and risk for specific cancers in patients with PD in Korea.
Using data from the Korean National Health Insurance Database, we analysed 52,009 patients diagnosed with PD between 2010 and 2015 and 260,045 individuals without PD. Patients previously diagnosed with cancer were excluded. The age- and sex-matched cohorts were followed up until 2016 for cancer development. Cox proportional hazards regression models were used to evaluate the relationship between PD and cancer.
Patients with PD had a lower overall cancer risk (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.74-0.82) after adjustment for multiple covariates during 2,022,852.6 person-years of follow-up. Patients with PD showed significantly lower risk of laryngeal cancer (HR, 0.45; 95% CI, 0.21-0.84), gastric cancer (HR, 0.72; 95% CI, 0.63-0.82), colorectal cancer (HR, 0.675; 95% CI, 0.60-0.76), liver cancer (HR, 0.80; 95% CI, 0.67-0.95), pancreatic cancer (HR, 0.75; 95% CI, 0.62-0.91), lung cancer (HR, 0.73; 95% CI, 0.63-0.84), leukaemia (HR, 0.49; 95% CI, 0.24-0.89), uterine cervical cancer (HR, 0.64; 95% CI, 0.40-0.99) and prostate cancer (HR, 0.78; 95% CI, 0.66-0.91).
This nationwide population-based cohort study revealed that patients with PD had lower overall cancer risk and lower risk of specific cancers. Contrary to the results of the recent Asian study, this large cohort study revealed that patients with PD were less likely to develop cancer than those without PD in Korea. Our results were consistent with those of previous Western studies, despite differences in ethnicity and environment.
帕金森病（PD）与癌症发展之间的关联存在争议，尤其是在亚洲。因此，我们进行了一项全国性基于人群的队列研究，以评估韩国 PD 患者的总体癌症风险和特定癌症的风险。
使用来自韩国国家健康保险数据库的数据，我们分析了 2010 年至 2015 年间诊断为 PD 的 52009 例患者和 260045 例无 PD 个体。排除了先前诊断患有癌症的患者。年龄和性别匹配的队列在 2016 年之前进行了癌症发展随访。使用 Cox 比例风险回归模型评估 PD 与癌症之间的关系。
在 2022852.6 人年的随访期间，调整了多种协变量后，PD 患者的总体癌症风险较低（风险比[HR]，0.78；95%置信区间[CI]，0.74-0.82）。PD 患者的喉癌（HR，0.45；95%CI，0.21-0.84）、胃癌（HR，0.72；95%CI，0.63-0.82）、结直肠癌（HR，0.675；95%CI，0.60-0.76）、肝癌（HR，0.80；95%CI，0.67-0.95）、胰腺癌（HR，0.75；95%CI，0.62-0.91）、肺癌（HR，0.73；95%CI，0.63-0.84）、白血病（HR，0.49；95%CI，0.24-0.89）、子宫颈癌（HR，0.64；95%CI，0.40-0.99）和前列腺癌（HR，0.78；95%CI，0.66-0.91）的风险显著降低。
这项全国性基于人群的队列研究表明，PD 患者的总体癌症风险较低，特定癌症的风险也较低。与最近的亚洲研究结果相反，这项大型队列研究表明，韩国 PD 患者发生癌症的风险低于无 PD 患者。尽管种族和环境存在差异，但我们的结果与之前的西方研究结果一致。
